Internal Electron Transfer between Hemes and Cu(II) Bound at Cysteine beta 93 Promotes Methemoglobin Reduction by Carbon Monoxide*

Celia Bonaventuraab, Gerald Godettea, Shirley Tesha, David E. Holmc, Joseph Bonaventuraad, Alvin L. Crumblisse, Linda L. Pearcefg, and Jim Petersonhi

From the a Marine/Freshwater Biomedical Center, Duke University Marine Laboratory, Beaufort, North Carolina 28516, the c Department of Chemistry, the University of Alabama, Tuscaloosa, Alabama 35487-0336, the e Department of Chemistry, Duke University, Durham, North Carolina 27708, the f Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, and the h Department of Chemistry, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213

    ABSTRACT
Top
Abstract
Introduction
References

Previous studies showed that CO/H2O oxidation provides electrons to drive the reduction of oxidized hemoglobin (metHb). We report here that Cu(II) addition accelerates the rate of metHb beta  chain reduction by CO by a factor of about 1000. A mechanism whereby electron transfer occurs via an internal pathway coupling CO/H2O oxidation to Fe(III) and Cu(II) reduction is suggested by the observation that the copper-induced rate enhancement is inhibited by blocking Cys-beta 93 with N-ethylmaleimide. Furthermore, this internal electron-transfer pathway is more readily established at low Cu(II) concentrations in Hb Deer Lodge (beta 2His right-arrow Arg) and other species lacking His-beta 2 than in Hb A0. This difference is consistent with preferential binding of Cu(II) in Hb A0 to a high affinity site involving His-beta 2, which is ineffective in promoting electron exchange between Cu(II) and the beta  heme iron. Effective electron transfer is thus affected by Hb type but is not governed by the R left-right-arrow  T conformational equilibrium. The beta  hemes in Cu(II)-metHb are reduced under CO at rates close to those observed for cytochrome c oxidase, where heme and copper are present together in the oxygen-binding site and where internal electron transfer also occurs.

    INTRODUCTION
Top
Abstract
Introduction
References

Hemoglobin (Hb)1 functions as an oxygen carrier only when reduced and is so maintained in vivo through enzymatic NADPH-driven reduction reactions (1-4). It has been suggested that low levels of copper, normally present in vivo, promote Hb oxidation and that copper-induced oxidation contributes to loss of reducing potential in the red cell and eventual red cell deterioration. Copper is toxic at elevated levels, and the mechanism of toxicity involves increased rates of Hb oxidation with adverse side reactions such as increased cell membrane oxidation (1, 2, 5, 6).

We owe much of our understanding of copper-induced oxidation of Hb to the work of Winterbourn and Rifkind and co-workers (1, 5), who showed that copper-induced oxidation of oxyHb occurs through an internal electron transfer pathway between the iron atoms of the beta  chain hemes and copper bound at or near the beta 93 sulfhydryls. They found that Cu(II) binding to Hb facilitates the oxidation process through this internal pathway only when the amount of Cu(II) exceeds that bound at unreactive high affinity sites, which in Hb A0 includes the beta 2 histidine residues. As a consequence, the oxidative reaction proceeds less readily at low copper concentrations in Hb A0 than in the human Hb variant Hb Deer Lodge (beta 2His right-arrow Arg) and in Hbs of species that lack His-beta 2 (1). Hb Deer Lodge has higher oxygen affinity and increased anion sensitivity and is more readily oxidized than Hb A0 (7, 8). We have used Hb Deer Lodge and Hb A0 in the present studies in which we show that CO/H2O-driven electron transfer can bring about a reduction of the beta  chain hemes that utilizes this internal electron transfer pathway.

Previous studies carried out in our laboratories have shown that Fe3+ in isolated heme (hemin), in Hb, in cytochrome c oxidase and in several other oxygen-binding proteins can become reduced when maintained under an atmosphere of CO, with the half-cell reaction given in Eq. 1 driving the overall process (9).
<UP>CO</UP>+<UP>H<SUB>2</SUB>O</UP> → <UP>CO<SUB>2</SUB></UP>+<UP>2H<SUP>+</SUP></UP>+<UP>2e<SUP>−</SUP></UP> (Eq. 1)
In the following we refer to metal reduction coupled to this half-reaction as CO/H2O-driven reduction. The overall free-energy change is clearly dependent upon the identity and environment of the metals reduced. The process of reduction under CO was called "autoreduction" by previous workers (10-14) who noted that cytochrome c oxidase, with two constituent electron-accepting metal centers in the oxygen-binding site, becomes reduced under CO. Heme a3 in the oxygen-binding site of the oxidase is typically reduced in less than an hour, with a much slower (overnight) incubation required to bring about reduction of heme a. The details of the reduction of cytochrome c oxidase are not well understood, and there are clearly competing processes that have hindered elucidation of the mechanism (15).

We now report that Cu(II) addition to metHb dramatically increases the rate of heme reduction under CO. We show that Cu(II) is reduced to Cu(I) as the reaction proceeds and that the enhanced rate of reduction is inhibited by sulfhydryl reagents such as N-ethylmaleimide. The data indicate the existence of an internal pathway that is used for electron exchange between the heme iron and the bound Cu(II).

    EXPERIMENTAL PROCEDURES

Samples of native adult human hemoglobin (Hb A0) and Hb Deer Lodge were prepared by the ammonium sulfate method, chromatographically purified, and stripped of organic phosphate cofactors as described previously (7). Horse Hb was prepared similarly but without chromatographic purification. The samples were typically dialyzed against 0.05 M Tris at pH 8.3 with selected anions as desired. Concentrations and compositions of samples were determined spectrophotometrically, using Hewlett-Packard 8451 and 8453 Diode Array spectrophotometers for routine measurements and a Perkin-Elmer lambda 6 dual beam-scanning spectrophotometer for higher resolution work. Samples were usually measured in 1-cm path length cuvettes, but cells with 2-mm path lengths were used to obtain spectral data on samples whose optical density would have gone beyond the linear response range of these instruments. Oxidized (met)Hb samples were made by treatment with potassium ferricyanide at 1.2-fold excess over heme. Sequential Sephadex G-25 chromatographies (high salt then no salt) were used to remove free and bound ferricyanide and ferrocyanide from the metHb samples. The amounts of oxidized Hb (metHb), deoxyHb, oxygenated Hb (oxyHb), carbon monoxyHb (CO-Hb), and hemichrome were determined by spectral analysis. Samples that contained any detectable hemichrome were discarded. The stock Hb solutions, typically 1-2 mM in heme units (iron-porphyrin units), were stored in liquid nitrogen prior to use. Sodium dithionite at 2 mg/ml was used as a reductant to obtain spectra of the fully reduced proteins. Hb with only the beta  chain hemes oxidized was prepared by addition of a 5-fold excess of CuSO4 over oxyHb. It has been shown (2, 16, 17) that under these conditions the beta  chain hemes are selectively oxidized, whereas the alpha  chain hemes remain in the reduced, ferrous state.

Isolation of alpha  and beta  chains of Hb A0 was accomplished by use of a modified version of established methods in which para-hydroxymercuribenzoate binds to SH groups and encourages dissociation of the Hb tetramer (18). Our modifications consisted of carrying out the separations at 4 °C, using chromatographies with CMC cellulose (for beta  chains) and DEAE cellulose (for alpha  chains) that effectively separate the chains. Regeneration of the SH groups of the beta  chains was done by treatment with beta -mercaptoethanol to reduce SH groups, followed by chromatography through DEAE-cellulose to remove para-hydroxymercuribenzoate. Tetramers of beta  chains form spontaneously after SH groups are regenerated.

The free SH groups of Hb (at position beta 93) were blocked by treating Hb A0 with N-ethylmaleimide (NEM) at a protein-to-reagent ratio of 1:3. The reaction was carried out at 37 °C for 1 h with the reactants in 0.05 M bis-Tris, pH 7.2, followed by Sephadex G-25 chromatography to separate the Hb from the low molecular weight reagent.

Carboxypeptidase A-digested Hb A0 (HbCPA) was prepared by treating the CO derivative of Hb A0 with carboxypeptidase A (Sigma, type 1, diisopropyl fluorophosphate) at an enzyme-to-protein ratio of 1:50. The mixture was incubated at 37 °C for 2 h and then dialyzed at 4 °C against 0.05 M Tris buffer, pH 8.3. This enzymatic digestion under the conditions employed removes the C-terminal His and Tyr of the beta  chains as verified by electrospray ionization mass spectrometry.

Cu(II)-metHb complexes were made by adding CuSO4 to metHb at indicated ratios of copper to heme. Hb samples in some cases were treated with 5-fold excess of Cu(II) and then stripped of unbound or loosely bound copper by passage through a Chelex resin column. In other experiments, the copper-Hb complexes were made by addition of copper at the desired ratio of copper to heme without subsequent Chelex treatment. Elemental analysis of samples by atomic absorption spectroscopy (Perkin-Elmer 5000) following copper treatment validated the copper:iron ratios used and demonstrated that our Chelex chromatography of samples treated with a 5-fold excess of copper typically reduced the copper:heme ratio to about 0.6:1, consistent with retention of copper at unreactive high affinity sites and partial retention of copper at the lower affinity sites associated with electron transfer to the heme. Prolonged exposure to Chelex eventually removes all Cu.

Incubations under CO were done with chemically pure grade (<= 99.5% purity) CO gas provided by National Welders, Inc. For visible-region spectroscopy of copper-Hb complexes, CO gas was added to tonometers containing thoroughly deoxygenated metHb samples. Deoxygenation was accomplished by multiple stages of sequential evacuation and purging with argon or nitrogen to ensure that no oxygen was present in the samples before CO incubation was begun. For EPR measurements, incubations of samples under CO were done for time intervals indicated under "Results" and immediately frozen in liquid nitrogen in EPR tubes for assays. Aqueous CuSO4 in the absence of Hb or other proteins was incubated in MES buffer with IHP at pH 6, 20 °C. Sodium dithionite (2 mg/ml) was added after variable periods of incubation under CO to generate the spectra of the fully reduced proteins.

EPR spectra of Hbs at about 0.5 mM in heme were recorded on a hybrid machine consisting of a Varian E109E spectrometer console used to provide the field modulation to a Bruker B-E 25 magnet, with an ER 082 power supply and a B-H 15 field controller, plus a Varian E102 microwave bridge coupled to a V-453.3 cylindrical cavity. Temperature control was effected by means of an Oxford Instruments ESR 900 liquid helium flow cryostat and accessories. The g values of samples were measured with reference to diphenylpicrylhydrazyl. Spin concentrations were determined by double integration using Cu(II)-EDTA, equine ferricytochrome c, and a quantitatively high spin methemoglobin sample as integration standards for the g = 2, 3, and 6 regions of spectra, respectively.

    RESULTS

Visible Spectroscopy of the CO/H2O-driven Reduction of Cu(II)-MetHb Complexes-- Heme reduction brought about by incubation under CO allows for binding of CO, so that time courses show a disappearance of the spectral features of metHb and an appearance of the features of CO-Hb. There are generally good isosbestic points for the transition, with the exception of experimental conditions described later. Cu(II) addition significantly enhances the rate of metHb reduction, with enhanced rates evident only for the beta  chains of the Hb tetramer.

Specificity for beta  chains in Cu(II)-enhanced rates of reduction is supported by the fact that there are similar reaction kinetics for half-reduction of a Cu(II)-metHb complex, alpha (III)2beta (III)2, and for full reduction of a half-metHb preparation, alpha (II)2beta (III)2, with the same ratio of Cu(II) to heme. Fig. 1 shows the spectral changes in these two samples brought about by incubation under CO. Good isosbestic points between the met and CO derivatives are observed in both cases. The fully oxidized Hb becomes half-reduced in about 10 h, with a half-time of beta  chain reduction of about 4.5 h. For the copper-Hb complex with only the beta  chains oxidized, the half-time for reduction is also about 4.5 h. We conclude that it is the reduction of the beta  chain hemes that is appreciably increased in rate by copper addition and that the oxidation state of the partner chains is not a major determinant of the reduction rate.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1.   Spectral changes during copper-enhanced CO/H2O-driven reduction. The spectral changes shown were brought about by incubation of Cu(II)-treated Hb under 1 atm CO at 25 °C in 0.05 M Tris-HCl at pH 8.3. The Hb samples were 13 µM in heme and had Cu(II)-to-heme ratios of 0.5. A, MetHb A0 reduction proceeds "rapidly" only to the half-reduced condition, as shown by spectra taken at 2-h intervals. B, full reduction of half-met (alpha (II)2beta (III)2) Hb A0 is shown by spectra taken at 3-h intervals. See text for details.

Isolated beta  chains were prepared as described under "Experimental Procedures." After regeneration of SH groups, the beta  chains spontaneously form tetramers. The beta 4 tetramers do not show an increase in the rate of CO/H2O-driven reduction when observed at a copper:heme ratio of 0.5 (Table I). However, Cu(II)-enhanced rates of reduction are observed when the copper:heme ratio is raised to 2. Rates of reduction under CO at this Cu(II) level are appreciably enhanced over controls. Rate estimates at this Cu(II) level are not given in Table I because of uncertainties associated with some sample precipitation during these experiments. The requirement for higher Cu(II) levels in beta 4 tetramers can be explained by the fact that each beta  chain has a high affinity copper-binding site at the beta 2 position that would be expected to be ineffective in electron transfer. The failure to see copper-enhanced rates at ratios below 1 copper per heme is thus an indication that Cu(II) has limited access to effective electron transfer sites in the beta 4 tetramers. We conducted an additional experiment to determine if the requirement of high copper:heme levels for reduction of beta 4 tetramers was due to some artifactual modification of the beta  chains during the isolation procedure. We found that the beta  chains do become reduced under CO at a copper:heme ration of 0.5 when present in half-met alpha (II)2beta (III)2 tetramers that were made by 1:1 mixing of the isolated beta  chains with reduced alpha  chains. This experiment with reconstituted half-met tetramers gave results similar to those shown in Fig. 1B. This confirmed that the isolated beta  chains were selectively reduced under CO after copper addition.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Effect of Cu(II) on apparent rate constants for CO/H2O-driven reduction of heme in various proteins under varied conditions
Reduction was initiated by putting the indicated sources of Fe(III) under 1 atm CO. The apparent first-order fast (k1) and slow (k2) rate constants were calculated by monitoring the spectral changes at 406 nm associated with reduction of Met (Fe(III)) heme and fitting the time courses to two exponential components. Controls are samples run in the absence of Cu(II). Unless otherwise noted, the samples were 13 µM in heme and were in 0.05 M Tris, pH 8.3, at 25 °C. When added, IHP was present at 40-fold excess over heme.

The effects of varied levels of Cu(II) on the time courses of beta  heme reduction under CO were explored. As shown in Fig. 2, with no copper present there is very little reduction of metHb A0 or metHb Deer Lodge after a 24-h incubation under CO (data shown only for Hb A0, open circles). The small extent of reduction of the copper-free metHb A0 control is consistent with our previous work that established the half-time for metHb A0 reduction under CO to be about 1000 h at 1 atm pressure. When the process is carried out with a copper:heme ratio of 0.25, the process is only slightly increased in rate for Hb A0 but appreciably increased in rate for Hb Deer Lodge (beta 2His right-arrow Arg). The CO/H2O-driven reduction of metHb A0 occurs more quickly at elevated Cu(II) levels. As shown, at a copper:heme ratio of 0.7, approximately one-half of metHb A0 becomes reduced at a copper-enhanced rate, attributable to preferential reduction of the beta  chains (see above). The remainder of the reaction is ascribed to the reduction of the alpha  chains. This much slower phase is less sensitive to copper addition. No efforts were made to investigate copper-Hb interactions at ratios above 1.0 copper:heme, since ratios greater than 0.5:heme can result in gradual protein precipitation (1) and disulfide formation (2).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of Cu(II) on time courses of CO/H2O-driven reduction of metHb A0 and metHb Deer Lodge. The fraction of oxidized Hb at the indicated times was calculated independently from data collected at two wavelengths (such as 406 and 419 nm for measurements in the Soret region) and then averaged. The optical path lengths of cuvettes were selected to allow for readings in the linear range of spectrophotometers used. Samples were in 0.01 or 0.05 M Tris-HCl at pH 8.3 and were incubated under 1 atm CO at 25 °C. Open circles, copper-free metHb A0; closed circles, metHb A0 (0.17 mM in heme) with a ratio of 0.25 copper to heme; closed squares, metHb Deer Lodge (0.51 mM in heme) with a ratio of 0.25 copper to heme; closed diamonds, metHb A0 (0.02 mM in heme) with a ratio of 0.38 copper to heme; closed triangles, metHb A0 (0.02 mM in heme) with a ratio of 0.74 copper to heme.

The time courses of heme reduction observed over a 24-h period were generally well fit by assuming that they are composed of two exponential phases. Apparent rate constants for the two phases, obtained under varied conditions, are given in Table I. The apparent first-order rate constant of the first phase (k1) reflects the Cu(II)-sensitive rate of beta  chain reduction. The apparent first-order rate constants for the second phase (k2) are like those of the copper-free controls.

The copper:heme ratios indicated in Table I were established by Cu(II) addition to thoroughly deoxygenated metHb samples (exceptions are indicated). Multiple stages of sequential de-aeration and purging with argon or nitrogen ensured that no oxygen was present in the samples before CO incubation was begun, generally about 20 min after copper addition. That reactive oxygen species are not involved in these reactions was verified by observing similar time courses of CO/H2O-driven reduction in the presence of added catalase and/or superoxide dismutase. Greatly enhanced rates of heme reduction for Cu(II)-metHb complexes under CO relative to samples without copper were observed in the Soret region with dilute samples (about 10 µM in heme) and in the 500-650-nm wavelength region with much more concentrated samples (about 500 µM in heme) in 2-mm path length cells. The phenomena observed are not artifacts of dissociation, as verified by observing similar behavior over a wide protein concentration range and use of high pressure liquid chromatography that showed no experimentally detectable subunit dissociation in the high concentration samples.

At low levels of copper (<= 0.25 copper:heme), the rate and extent of reduction of metHb Deer Lodge (closed squares in Fig. 2) are clearly more affected by copper addition than reduction of metHb A0 (closed circles). Horse Hb, also lacking His-beta 2 residues, behaves like Hb Deer Lodge in having an appreciable copper-enhanced phase of CO/H2O-driven reduction at 0.25 copper:heme (Fig. 2 and Table I). These results mirror the EPR results presented in the next section. The structural explanation for the difference in copper sensitivity exhibited by metHb A0, horse metHb, and metHb Deer Lodge is that the His-beta 2 residues of Hb A0 are key residues in high affinity copper-binding sites that are ineffective in electron exchange with the heme.

Although there are theoretically two high affinity copper-binding sites per tetramer (0.5 copper per heme) in Hb A0, significant enhancement of its reduction rate under CO occurs at Cu(II) levels above 0.25 copper:heme, indicating a distribution of copper to the sites responsible for CO/H2O-driven reduction before all "high affinity" sites are filled. A similar copper concentration dependence was reported by Louro and co-workers (19) in their studies of copper-induced oxidation of the beta  chains of Hb.

Sample treatment can alter the time courses of CO-driven reduction by altering the distribution or access of copper to the "effective" copper-binding sites. As illustrated in Fig. 3, significant inhibition of the copper effect occurs when copper-binding sites near the beta 93 sulfhydryl groups are blocked by treatment with N-ethylmaleimide (NEM). NEM treatment also results in a slight increase in the rate of reduction of the copper-free control. Variable time courses, presumably reflecting variable distribution of Cu(II) among the binding sites, can also be achieved by variations in sample handling, as illustrated by the two lower (faster) time courses of Fig. 3 where samples gave significantly different time courses of reduction as a consequence of different sample handling procedures.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Time courses of CO/H2O-driven reduction of Cu(II)-metHb. Hb samples were incubated under 1 atm CO in 0.05 M Tris-HCl buffer, pH 8.3, at 25 °C under varied experimental conditions. Open triangles, copper-free metHb A0 treated with NEM; closed triangles, NEM-treated metHb A0 after addition of 0.5 copper to heme; closed circles, metHb A0 with a ratio of 0.6 copper to heme (established by exposure of metHb to Cu(II) at a ratio of 5 coppers to heme, followed by Chelex treatment prior to incubation under CO); closed diamonds, metHb A0 with a ratio of 0.38 copper to heme (established by direct Cu(II) addition to deoxygenated metHb prior to CO incubation).

The rates and time courses (within experimental variability) of CO/H2O-driven reduction are unchanged when Cu(II)-metHb complexes are incubated under progressively lower CO levels over a range of solution concentrations from 1 to 0.05 mM CO. Within this range of CO concentrations, good isosbestic points are typically observed between the met and CO derivatives of Hb, and the decreases in absorbance at 406 nm (metHb disappearance) and the increases in absorbance at 419 nm (CO-Hb appearance) have the same time dependence. The CO concentration independence and the wavelength independence of the process together indicate that the Fe(III) (met) and CO-Hb forms are the only significantly populated species and that something other than CO concentration is rate-limiting in the transition toward CO-Hb. Intermediate species are, however, apparent when incubation is carried out at low CO levels and IHP is present. Under progressively lower CO concentrations (<0.25 mM) in the presence of IHP, the time courses observed at 406 and 419 nm become increasingly distinct, and the isosbestic point between met and CO-Hb is not maintained.

We examined the CO/H2O-driven reduction of Cu(II) complexes of metHb A0 under a number of experimental conditions, with results summarized in Table I. Many of our experiments were performed at relatively low protein concentration (10-15 µM in heme) where the concentration of dimeric forms of metHb would be appreciable. Remarkably, there are no systematic differences in reduction rates when the heme concentration is varied over the range of 10 to 500 µM. This is evidence that the internal electron transfer responsible for heme reduction is governed by tertiary rather than quaternary conformational states. This conclusion was also supported by studies reported below, using T-state stabilization by IHP and R-state stabilization by digestion with carboxypeptidase A.

Strong allosteric effectors such as inositol hexaphosphate (IHP) can shift R-state metHb toward the T-state (20). IHP addition results in an approximately 2-fold decrease in the half-time for the rapid (beta  chain) phase of reduction at pH 8.3. This suggested that copper-enhanced reduction of metHb might be slower in its T-state conformation. We then looked for possible pH effects on the IHP-induced changes in rate, since IHP stabilization of the T-state would be expected to be more evident at low pH. However, the rate of reduction in the presence of IHP is appreciably faster at pH 7 than at pH 8.3. The pH shift alone caused only a minor alteration in reduction rate. Lower rates of reduction would have occurred at pH 7 if the IHP effect was due to a T-state shift. The altered efficacy of Cu(II) in the presence of IHP thus does not follow the pattern expected for R left-right-arrow  T shifts of quaternary conformation.

We further examined the possible effect of Hb conformation on the reductive process by monitoring the CO/H2O-driven reduction of metHb after modification by digestion with carboxypeptidase A (HbCPA). This digestion removes the C-terminal His and Tyr residues of the beta  chains, strongly stabilizes the R-state conformation, and inhibits the IHP-induced shift toward the T-state (21, 22). HbCPA controls behaved like the undigested protein, so that in the absence of copper metHbCPA became reduced under CO with an apparent rate constant similar to that of metHb A0 (k2 = 0.006 h-1). In the presence of Cu(II) at 0.5 copper:heme, half-reduction of metHbCPA was enhanced in rate over that of the copper-free controls. The rate enhancement was relatively small, so that beta  chains became reduced at a rate about half that characteristic of the undigested protein. Constraining the protein to the R-state by this modification thus caused a decreased rate of reduction. Addition of IHP increased the rate to somewhat greater than observed for undigested protein in the absence of IHP, with a half-time for reduction of the fast phase of about 1 h. The rate increase brought about by IHP on the reduction of metHbCPA is in marked contrast to results obtained with metHb A0, where the reductive process is slowed by the presence of IHP (see Table I). We conclude from these comparative studies that the rate of reduction is governed by tertiary effects on the internal electron transfer pathway and not by the pattern of T left-right-arrow  R shifts of quaternary conformation that govern oxygen binding.

The rate of the reductive process is clearly affected by the level of Cu(II) that is bound at a site that is effective in internal electron transfer. In our studies with metHbCPA, we noted that the magnitude of the fast phase of reduction is not as great as that for metHb A0 at a comparable copper:heme ratio. The reduced magnitude of the fast phase of reduction is probably due to sequestration of copper in non-reactive sites. The magnitude of the fast phase of reduction after addition of the allosteric effector IHP is not reduced, suggesting that IHP binding alters the copper distribution toward sites that are effective in electron transfer.

Visible spectroscopy using the Cu(I)-dependent absorption changes of bathocuproin at 483 nm (23) demonstrated that significant amounts of Cu(II) are reduced to Cu(I) when protein-free CuSO4 is incubated under CO. EPR measurements described below confirmed that incubation of Cu(II) under CO led to its reduction. Since Cu(I) is a potential heme reductant, we investigated the possibility that addition of Cu(I) would bring about the reduction of beta  chain hemes in Hb. For this study thoroughly degassed solutions of Cu(I) as CuCl at a ratio of 0.5 copper:heme were added to deoxygenated metHb in tonometers. No appreciable spectral shifts were observed. We then added 1 atm CO. There was no spectral indication of heme reduction after 24 h (data not shown), indicating that under these conditions, free Cu(I) does not directly contribute to reduction of metHb. Exposure to air gave Cu(II)-metHb complexes equivalent to ones prepared by our normal procedures that were susceptible to CO/H2O-driven reduction.

EPR Studies of the CO/H2O-driven Reduction of Cu(II)-MetHb Complexes-- Experiments described here demonstrate the crucial role of copper in the mechanism of reduction of Cu(II)-metHb complexes. As reported below, both copper and heme reduction occur to an appreciable extent when Cu(II)-metHb complexes are incubated under CO. We also found that maintaining various preparations of aqueous Cu(II) (in the absence of protein) overnight under 1 atm CO leads to the disappearance of at least 20% of the initial Cu(II) EPR signal as a result of CO/H2O-driven Cu(II) reduction. Thus, Cu(II) in the absence of heme is susceptible to reduction under CO.

The EPR spectrum of human metHb A0 at pH 8.3 typically contains two distinct sets of signals, as shown in Fig. 4A, that arise from high spin ferric hemes (g = 5.9 and 2.0) and low spin ferric hemes (gzyx = 2.59, 2.18, and 1.83). These two kinds of signals correspond to situations in which the sixth ligand to iron is H2O and OH- respectively (24, 25).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of Cu(II) and CO on EPR spectra of metHb A0. X-band EPR spectra are shown for samples at pH 8.3, 22 K with Hb at 0.51 mM in heme, obtained with 2 milliwatts microwave power; 5 G modulation amplitude; 4 × 104 receiver gain. A, copper-free metHb A0. B, metHb A0 with 0.25 mM CuSO4. C, same as in B but maintained under 1 atm CO for 1 h prior to freezing. D, same as in B but maintained under 1 atm CO for 24 h prior to freezing.

EPR signals, attributable to Cu(II) in a Cu(II)-metHb complex, appear following the addition of 0.5 eq (per heme) of CuSO4 to anaerobic solutions of metHb, as shown in Fig. 4B. These signals were first observed by Bemski and co-workers (26, 27) and have since been confirmed by several other groups for the complex of Cu(II) with Hb A0. Within our experimental uncertainty, the EPR signals we observed after Cu(II) addition to oxidized Hb A0 are indistinguishable from those previously reported where Cu(II) was added to the deoxy derivative. Fig. 5A, showing enlarged details of Fig. 4B, illustrates the 9-line superhyperfine pattern indicative of square-planar coordination of the Cu(II) by four electronically equivalent nitrogen ligands (27, 28). As reported previously by Antholine et al. (29), this pattern is the spectral signature of the high affinity Cu(II) binding site (site 3 in Antholine's terminology), located near the N terminus and His-beta 2 of each beta  chain. Not all Cu(II) sites are occupied at a ratio of copper:heme of 0.5:1, and most of the Cu(II) binds preferentially to the high affinity site. Consequently the distinctive signature of Cu(II) at the lower affinity site at or near the Cys-beta 93 (site 2 in Antholine's terminology) is not readily observed in the spectrum. Fig. 5B shows that this superhyperfine pattern is absent in Hb Deer Lodge which lacks His-beta 2.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 5.   EPR spectra of Cu(II)-metHb derivatives. X-band EPR spectra are shown for samples at pH 8.3, 22 K, obtained with 5 milliwatts microwave power; 5 G modulation amplitude; 4 × 104 receiver gain. A, metHb A0, 0.51 mM in heme with 0.25 mM CuSO4; 41 K. B, metHb Deer Lodge, 0.55 mM in heme with 0.28 mM CuSO4; 40 K.

We fortuitously prepared an uncomplexed metHb sample that contained no measurable low spin component. By using this sample as an integration standard for the g = 6 region, we determined that the heme groups of Fig. 4A were at least 50% high spin. Upon complexation with Cu(II) (Fig. 4B), the heme groups were 30% (±10%) high spin. Apparently all the added Cu(II) contributed to the intensities of resulting spectra so that there was no clear evidence for coupling between the ferric hemes and Cu(II), although we would not have been able to detect low levels (10%, or less) of Cu(I) or anti-ferromagnetically coupled (and thus EPR silent) species.

Fig. 4C shows that there is no significant change in the EPR spectrum if the Cu(II)-metHb A0 complex is incubated at room temperature under 1 atm CO for 1 h prior to freezing in the EPR tube. However, if the CO incubation is continued overnight, some heme and copper reduction takes place as shown in Fig. 4D. In this case about 20% of the low spin heme signal and about 20% of the Cu(II) signal disappears (cf. Fig. 4, C and D) as a result of reduction. This result is consistent with spectral changes indicative of heme reduction observed by visible spectroscopy (see previous section).

Fig. 6A shows that the EPR spectrum of metHb Deer Lodge prepared at pH 8.3 contains the same high spin and low spin ferric heme signals as found for metHb A0, but the ratio of these two components differs in the two hemoglobins. Typical Hb Deer Lodge samples contained only 15% (±5%) of the high spin component. Addition of 0.5 eq (per heme) of CuSO4 leads to the spectrum of Fig. 6B. Due to the overlapping low spin ferric heme signals in the present spectra, we cannot determine the EPR parameters for the Cu(II) signal in the Hb Deer Lodge complex with high precision, but we note that, within our experimental uncertainty, they are indistinguishable from those previously reported for a "low affinity" Cu(II)-binding site in deoxyhemoglobin A0 that is associated with the Cys-beta 93 residue, located less than 10 Å from the beta  chain heme (30). It is this copper-binding site that has been associated with internal electron transfer in copper-induced oxidation of heme (19). Moreover, the Cu(II)-metHb complex of Hb Deer Lodge does not show the 9-line superhyperfine pattern associated with Cu(II) binding at or near the His-beta 2, indicating that this site is absent (Fig. 5B). The Cu(II) complexes of other Hbs without a His-beta 2, such as horse hemoglobin (1) and cat hemoglobin (30), have also been shown to give EPR spectra that lack the 9-line superhyperfine pattern.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of Cu(II) and CO on EPR spectra of metHb Deer Lodge. X-band spectra are shown for samples at 0.55 mM in heme at pH 8.3 at 21 K, obtained with 2 milliwatts microwave power; 10 G modulation amplitude; 2.5 x 104 receiver gain. A, metHb Deer Lodge. B, metHb Deer Lodge with 0.28 mM CuSO4. C, same as in B but maintained under 1 atm CO for 1 h prior to freezing. D, same as in B but maintained under 1 atm CO for 17 h prior to freezing.

Incubation of the Cu(II)-metHb Deer Lodge complex under CO leads to strikingly different results compared with the Cu(II)-metHb A0 complex. After 1 h there is 20-30% reduction of the hemes and 30-40% reduction of the copper, as shown in Fig. 6C. After 17 h, some 60-70% of both hemes and copper have been reduced as shown in Fig. 6D. The structural explanation for the greater extent of reduction in this case is that copper is more available at the effective site for electron transfer in Hb Deer Lodge, since its beta 2His right-arrow Arg substitution eliminates the high affinity copper-binding site found in Hb A0. This result of heme and copper reduction mirrors previous reports on heme oxidation (1) where more copper is required for oxidation of the beta  chains in Hb A0 than in Hbs like Hb Deer Lodge that lack His-beta 2 residues.

The site of copper binding clearly determines its ability to participate in the CO/H2O-driven reduction reaction, as evidenced by the much slower rate of reduction of Hb A0 relative to Hb Deer Lodge (beta 2His right-arrow Arg) at low copper levels (Figs. 4 and 6). Copper is clearly a partner in CO/H2O-driven reduction of the Cu(II)-metHb complexes since both heme and copper reduction occurs for Cu(II)-metHb complexes incubated under CO.

    DISCUSSION

We previously demonstrated that a reaction similar to the water-gas shift reaction, driven by the oxidation of CO/H2O to CO2 + 2H+ + 2e- (Equation 1), can drive the reduction of a number of heme proteins, with free energy changes dependent on the type of heme protein and the experimental conditions (9). The results presented here show that Cu(II) addition enhances the rate of reduction of the beta  chains of metHb under CO, implicating beta  heme and Cu(II) as acceptors of the two electrons generated by Equation 1. The EPR measurements show reduction of Fe(III) and Cu(II) when metHb is incubated under CO in the presence of Cu(II). The beta  chain hemes in Cu(II)-metHb assemblies exhibit rates of CO/H2O-driven reduction that are roughly 1000-fold faster than those for Hb in the absence of Cu(II). The fastest beta  chain reductions we observed have half-times of about 1 h, only slightly less rapid than previously reported for the CO/H2O-driven reduction of heme a3 and copper of the oxygen-binding site of cytochrome c oxidase (9).

Clearly, the heme and copper together enhance the rate of CO/H2O oxidation that drives the reductive process in Cu(II)-metHb complexes. The rate enhancement makes use of an internal pathway of electronic communication in the Cu(II)-metHb complexes that is functionally similar to but structurally distinct from that of heme a3 and copper in cytochrome c oxidase. The differences are evident in the EPR spectra arising from these two systems, where the Cu(II) in the binuclear site of the oxidase, but not in the Cu(II)-metHb complexes, is EPR silent (31) due to an anti-ferromagnetic exchange interaction with heme a3 (Ref. 32 and references therein).

Scheme A and Scheme B as described below summarize two reaction sequences that are consistent with the available data. They are not mutually exclusive and differ primarily in how CO oxidation is coupled to the electron transfer reaction.


View larger version (11K):
[in this window]
[in a new window]
 
Scheme A.   M1 and M2 represent the oxidized forms of the two metal centers and M1- and M2- represent the reduced forms.

Scheme A invokes the generation of an intermediate as a result of CO attack on a metal hydroxide. This process limits the reaction rate at low CO concentration (less than 0.05 mM) and achieves saturation and becomes CO independent above 0.05 mM. Subsequently, as CO2 is released, an intermediate species is formed with two-electron reducing potential that is equivalent to a transient species with the reducing potential of a metal hydride (shown in quotes). A subsequent internal electron transfer process is postulated to be the rate-limiting step at high CO pressure, supported by the observed Cu(II) dependence of the reaction rate. In Hb, Fe(III) would serve as M1 and Cu(II) bound at or near Cys-beta 93 would serve as M2. Cu(II) bound at or near Cys-beta 93 in Hb is less likely to serve as M1 because this less hydrophobic environment would be less favorable for generation and distribution of electrons from the postulated intermediate to heme in the active site. The presence of a second electron acceptor, M2, in electronic communication with M1 is ultimately necessary for facile reduction of both metals and release of protons.

Under some conditions the partial oxidation of Fe(III) by Cu(II) may also play a role in utilizing the electrons provided by CO/H2O oxidation (Scheme B). Since Cu(II) can oxidize the heme Fe(II) of the chains of Hb (1), it is possible that the internal electron exchange pathway can allow for some population of a Fe(IV)-Cu(I) redox pair.
<AR><R><C><UP>Fe</UP>(<UP>III</UP>)<UP>–––Cu</UP>(<UP>II</UP>)</C><C><UP>↔</UP></C><C><UP>Fe</UP>(<UP>IV</UP>)<UP>–––Cu</UP>(<UP>I</UP>)</C></R><R><C><UP>CO/H<SUB>2</SUB>O</UP>+<UP>Fe</UP>(<UP>IV</UP>)</C><C><UP>→</UP></C><C><UP>CO<SUB>2</SUB></UP>+<UP>Fe</UP>(<UP>II</UP>)+<UP>2H</UP><SUP><UP>+</UP></SUP></C></R><R><C><UP>2CO</UP>+<UP>Fe</UP>(<UP>II</UP>)+<UP>Cu</UP>(<UP>I</UP>)</C><C><UP>↔</UP></C><C><UP>Fe</UP>(<UP>II</UP>)<UP>CO</UP>+<UP>Cu</UP>(<UP>I</UP>)<UP>CO</UP></C></R></AR>
<UP><SC>Scheme</SC> B</UP>
The lack of accurate redox potentials for these redox pairs as they exist in the protein prevents us from calculating the extent of such a process. However, as indicated by our results, as much as 10% of metHb is converted to a quickly CO-reducible form of Hb after 30 min of exposure to Cu(II) at a copper:heme ratio of 0.7. The absorption spectrum of this altered Hb form resembles that of ferryl Hb. Moreover, we found that the treatment of Hb with H2O2, known to promote ferryl Hb production, generates a state that is also readily reducible by CO, similar to the quickly CO-reducible fraction observed for Cu(II)-treated metHb. Creation of an oxyferryl heme intermediate is known to occur in peroxidase-catalyzed reactions, and is likely to occur in Hb when it mimics such chemistry (33). Furthermore, under conditions where the CO/H2O-driven reduction reaction does not show good isosbestic points between metHb and CO-bound forms of Hb, the inferred intermediates in the spectral transition have features that appear similar to those published for ferryl Hb (33).

This report deals exclusively with the Cu(II)-induced enhancement of the reduction of metHb under CO that is NEM-sensitive and utilizes an internal electron transfer pathway. Comparative studies revealed that the rate and extent of reduction of the Cu(II)-metHb complexes under CO are limited by the availability of Cu(II) at a site that allows for electron exchange with the beta  chain hemes. The sulfhydryl group at beta 93 is implicated in the process since Cu(II)-induced rate increases are inhibited when this residue is blocked by treatment with NEM. The beta  chain hemes are separated from Cys-beta 93 by only a single residue, the proximal histidine. Therefore, this histidine can be presumed to be part of the pathway between iron and copper bound at or near Cys-beta 93. It may constitute the entire pathway, since an effective electron transfer pathway would be created if Cu(II) bound at or near the Cys-beta 93 rearranged its binding site by displacing the N-2 proton of the imidazole of the proximal histidine. This rearrangement would create an imidazolate bridge between the heme iron and the bound copper and provide a short internal pathway for electron transfer. Our data are unable to support or refute an imidazolate bridge as the sole member of an internal electron transfer pathway.

We tested the hypothesis that metHb reduction proceeds via CO reduction of Cu(II), followed by Cu(I) coordination of the sulfhydryl of Cys-beta 93, followed by electron transfer to the heme group. However, experiments conducted with Cu(I) addition to metHb (with 0.5 Cu(I)/heme) showed no detectable heme reduction before or after incubation under 1 atm CO. It is possible that strong Cu(I) binding to Cys-beta 93 prevents Cu(I) from occupying the site where electron transfer is effective. There is some experimental basis for this possibility, since it has been shown that when Cu(II) is added to oxyHb, the Cu(II) changes its position with respect to Cys-beta 93 prior to Cu(II)-induced oxidation of the beta  chains (30). The alternative explanation is that Cu(I) does not promote heme reduction because of unfavorable energetics.

The rate of the process whereby Cu(II)-metHb becomes reduced when incubated under CO is affected by Hb type, by digestion with carboxypeptidase A, by IHP binding, and by reaction temperature. We investigated the possibility that these variations were due to alterations in allosteric equilibrium between quaternary conformations of high and low oxygen affinity. Although unable to bind oxygen, metHb is also switchable between these conformational states (20, 24). The rates observed for CO/H2O-driven reduction of the Cu(II)-metHb complexes did not, however, correlate with alterations in the R left-right-arrow  T equilibrium. Furthermore, the conformational equilibrium is very sensitive to pH, but the CO/H2O-driven reduction of Cu(II)-metHb complexes shows no appreciable pH sensitivity. No systematic changes were noted between experiments conducted at high concentration (500 µM in heme) where the percentage of dimers was confirmed to be vanishingly small and at low concentration (10 µM in heme) where the percentage of dimers was appreciable. We conclude that while the process is sensitive to protein conformation, the quaternary R left-right-arrow  T equilibrium is not the primary determining factor that establishes the rate or extent of this reductive process. The internal pathway may, however, be altered by structural changes induced by IHP binding, such as the movement of the A helices of the beta  chains toward the center of the molecule (34).

There is an increasing awareness that novel internal electron exchange pathways in proteins can be of physiological significance. Copper toxicity associated with Hb oxidation (1) and CO/H2O-driven reduction of metHb demonstrated in this paper are cases in point. We speculate that CO and NO may have parallel biological functions that are dependent upon internal electron exchange pathways in proteins. The pathway shown to be utilized in CO/H2O-driven reduction of metHb may also be involved in NO-driven reduction of metHb. We have shown, for example, that the rate of NO-driven reduction of metHb is, like CO/H2O-driven reduction, dependent on the nature of the Hb being reduced and, also as shown for CO/H2O-driven reduction, the rate of the process is independent of NO concentration over a wide range (35).

The importance of SH groups at beta 93 is indicated by the fact that they are highly conserved in mammalian Hbs. Our studies emphasize the role of these SH groups in the internal electron exchange pathway that links heme and SH groups and can lead to regeneration of active (Fe(II)) heme. In earlier studies, it was suggested that these SH groups are protective against Hb oxidation (1-3). Other studies have shown that the interactions of NO with these SH groups are critical for control of blood pressure and that formation of SNO-Hb is dependent upon the redox state of the heme, so that oxy- and metHbs differ in their rates of SNO-Hb formation (36). This redox dependence may be another consequence of the existence of the internal electron exchange pathway that allows for Cu(II)-enhanced rates of CO/H2O-driven reduction.

    ACKNOWLEDGEMENT

Expert analytical assistance provided by Dr. Robert Stevens of the Duke Mass Spectrometry Facility is gratefully acknowledged.

    FOOTNOTES

* This work was supported in part by National Institute of Environmental Health Sciences Center Grant ESO1908 (to C. B.) and National Institutes of Health Grant HL-58248 (to C. B. and A. L. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

b To whom correspondence should be addressed. Tel.: 252-504-7591; Fax: 252-504-7648; E-mail bona{at}duke.edu.

d Supported by the Tobacco Research Council and Apex Biosciences, Inc.

g National Institutes of Health Postdoctoral Fellow.

i Supported by grants from the American Heart Association (Alabama Affiliate), Biomedical Research Support Grant S07RR7151-14, and National Science Foundation Grant 9506817.

    ABBREVIATIONS

The abbreviations used are: Hb, hemoglobin; CPA, carboxypeptidase A; MES, 2-(N-morpholino)ethanesulfonic acid; NEM, N-ethylmaleimide; bis-Tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)- propane-1,3-diol.

    REFERENCES
Top
Abstract
Introduction
References
  1. Rifkind, J. M. (1981) in Metal Ions in Biological Systems (Sigel, H., ed), pp. 191-232, Marcel Dekker, Inc., New York
  2. Winterbourn, C. C. (1977) INSERM 70, 97-106
  3. Mansouri, A. (1979) Biochem. Biophys. Res. Commun. 89, 441-447[Medline] [Order article via Infotrieve]
  4. Yubisui, T., Matsuki, T., Tanishima, K., Takeshita, M., and Yoneyama, Y. (1977) Biochem. Biophys. Res. Commun. 76, 174-182[Medline] [Order article via Infotrieve]
  5. Winterbourn, C. C., and Carrell, R. W. (1977) Biochem. J. 165, 141-148[Medline] [Order article via Infotrieve]
  6. Bonomo, R. P., De Flora, A., Rizzarelli, E., Santoro, A. M., Tabbi, G., and Tonetti, M. (1995) J. Inorg. Biochem. 59, 773-784[CrossRef][Medline] [Order article via Infotrieve]
  7. Bonaventura, J., Bonaventura, C., Sullivan, B., and Godette, G. (1975) J. Biol. Chem. 250, 9250-9255[Abstract]
  8. Bonaventura, C., Tesh, S., Faulkner, K. M., Kraiter, D., and Crumbliss, A. L. (1998) Biochemistry 37, 496-506[CrossRef][Medline] [Order article via Infotrieve]
  9. Bickar, D., Bonaventura, C., and Bonaventura, J. (1984) J. Biol. Chem. 259, 10777-10783[Abstract/Free Full Text]
  10. Wharton, D. C., and Gibson, Q. H. (1968) J. Biol. Chem. 243, 702-706[Abstract/Free Full Text]
  11. Greenwood, C., Wilson, M. T., and Brunori, M. (1974) Biochem. J. 137, 205-215[Medline] [Order article via Infotrieve]
  12. Nicholls, P., and Chanady, G. A. (1981) Biochim. Biophys. Acta 634, 256-265[Medline] [Order article via Infotrieve]
  13. Brittain, T., and Greenwood, C. (1976) Biochem. J. 155, 453-455[Medline] [Order article via Infotrieve]
  14. Young, L. J. E., and Caughey, W. S. (1980) Fed. Proc. 39, 2090
  15. Young, L. J., and Caughey, W. S. (1987) J. Biol. Chem. 262, 15019-15025[Abstract/Free Full Text]
  16. Nagel, R. L., Bemski, G., and Pincus, P. (1970) Arch. Biochem. Biophys. 137, 428-434[Medline] [Order article via Infotrieve]
  17. Rifkind, J. M., Lauer, L. D., Chiang, S. C., and Li, N. C. (1976) Biochemistry 15, 5337-5343[Medline] [Order article via Infotrieve]
  18. Geraci, G., Parkhurst, L. J., and Gibson, Q. H. (1969) J. Biol. Chem. 244, 4664-4667[Abstract/Free Full Text]
  19. Louro, S. R. W., Perussi, J. R., and Tabak, M. (1986) Stud. Biophys. 113, 75-84
  20. Kilmartin, J. V. (1973) Biochem. J. 133, 725-733[Medline] [Order article via Infotrieve]
  21. Antonini, E., and Brunori, M. (1971) Hemoglobin and Myoglobin in Their Reactions With Ligands, North-Holland Publishing Co., Amsterdam
  22. Chiancone, E., Anderson, N. M., Antonini, E., Bonaventura, J., Bonaventura, C., Brunori, M., and Spagnuolo, C. (1974) J. Biol. Chem. 249, 5689-5694[Abstract/Free Full Text]
  23. Crumbliss, A. L., and Poulos, A. T. (1975) Inorg. Chem. 14, 1529-1534
  24. Perutz, M. F., Heidner, E. J., Ladner, J. E., Beetlestone, J. G., Ho, C., and Slade, E. F. (1974) Biochemistry 13, 2187-2200[Medline] [Order article via Infotrieve]
  25. Gadsby, P. M. A., and Thomson, A. J. (1990) J. Am. Chem. Soc. 112, 5003-5011
  26. Bemski, G., Arends, T., and Blanc, G. (1969) Biochem. Biophys. Res. Commun. 35, 599-605[Medline] [Order article via Infotrieve]
  27. Louro, S. R. W., and Bemski, G. (1977) J. Magn. Reson. 28, 427-431
  28. Hyde, J. S., Antholine, W. E., Froncisz, W., and Basosi, R. (1986) Advanced Magnetic Resonance Techniques in Systems of High Molecular Complexity, Vol. 2, pp. 363-384, Birkhauser Boston, Inc., Cambridge, MA
  29. Antholine, W. E., Taketa, F., Wang, J. T., Manoharan, P. T., and Rifkind, J. M. (1985) J. Inorg. Biochem. 25, 95-108[CrossRef][Medline] [Order article via Infotrieve]
  30. Antholine, W. E., Basosi, R., Hyde, J. S., and Taketa, F. (1984) J. Inorg. Biochem. 21, 125-136[CrossRef][Medline] [Order article via Infotrieve]
  31. Hartzell, C. R., and Beinert, H. (1974) Biochim. Biophys. Acta 368, 318-338[Medline] [Order article via Infotrieve]
  32. Day, E. P., Peterson, J., Sendova, M. S., Schoonover, J., and Palmer, G. (1993) Biochemistry 32, 7855-7860[Medline] [Order article via Infotrieve]
  33. Everse, J., Johnson, M. C., and Marini, M. A. (1994) Methods Enzymol. 231, 547-561[Medline] [Order article via Infotrieve]
  34. Arnone, A., and Perutz, M. F. (1974) Nature 249, 34-36[Medline] [Order article via Infotrieve]
  35. Alayash, A. I., Fratantoni, J. C., Bonaventura, C., Bonaventura, J., and Cashon, R. E. (1993) Arch. Biochem. Biophys. 303, 332-228[CrossRef][Medline] [Order article via Infotrieve]
  36. Jia, L., Bonaventura, C., Bonaventura, J., and Stamler, J. S. (1996) Nature 380, 221-226[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.